Epizyme Net Income 2011-2026 | EPZM

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Epizyme

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-251 M	-232 M	-170 M	-124 M	-134 M	-110 M	-132 M	-55 M	-3.48 M	-702 K	-21 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-702 K	-251 M	-112 M

Quarterly Net Income Epizyme

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-35.7 M	-55.5 M	-	-65.8 M	-64.4 M	-70.3 M	-66.2 M	-56.1 M	-58.5 M	-50.9 M	-56.4 M	-36.1 M	-48.5 M	-29.3 M	-22.9 M	-37.5 M	-29.1 M	-34.1 M	-36.2 M	-37.6 M	-28 M	-32.5 M	-35 M	-24.3 M	-28 M	-22.9 M	-22.2 M	-23.1 M	-25.8 M	-61.3 M	-15 M	-19.7 M	-13.4 M	-6.88 M	15.9 M	-9.7 M	-2.21 M	-7.5 M	-4.54 M	4.45 M	4.86 M	-5.47 M	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
15.9 M	-70.3 M	-30.6 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-514 M	-	2.43 %	$ 254 M	Germany
Graybug Vision GRAY	-29.6 M	-	-11.23 %	$ 9.65 M	USA
Apellis Pharmaceuticals APLS	22.4 M	$ 20.16	-2.61 %	$ 2.54 B	USA
Aptorum Group Limited APM	-4.27 M	$ 0.79	-6.17 %	$ 4.31 M	China
I-Mab IMAB	-1.47 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	603 M	-	-	$ 40.3 B	USA
Acer Therapeutics ACER	-26.2 M	-	2.71 %	$ 14 M	USA
Biophytis SA BPTS	-31.2 M	-	-13.47 %	$ 169 M	France
Ampio Pharmaceuticals AMPE	-8.63 M	-	-11.43 %	$ 502 K	USA
AbCellera Biologics ABCL	-146 M	$ 3.71	-2.88 %	$ 1.11 B	Canada
Athersys ATHX	-87 M	-	3.77 %	$ 22.4 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	-8.09 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	-5.46 M	-	-18.52 %	$ 27.3 M	Britain
AVEO Pharmaceuticals AVEO	-53.3 M	-	-	$ 521 M	USA
Axsome Therapeutics AXSM	-183 M	$ 164.05	-1.4 %	$ 8.16 B	USA
Brainstorm Cell Therapeutics BCLI	-11.6 M	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	84.9 M	-	-4.8 %	$ 255 M	USA
Burford Capital Limited BUR	172 M	$ 8.55	-2.06 %	$ 1.39 B	Britain
BridgeBio Pharma BBIO	-733 M	$ 64.53	-1.48 %	$ 12.4 B	USA
Adverum Biotechnologies ADVM	-131 M	-	-	$ 86.2 M	USA
CymaBay Therapeutics CBAY	-105 M	-	-	$ 3.45 B	USA
Институт стволовых клеток человека ISKJ	72.9 M	-	-	-	Russia
Avid Bioservices CDMO	-141 M	-	-	$ 789 M	USA
ARCA biopharma ABIO	-83.7 M	-	1052.0 %	$ 415 M	USA
BioMarin Pharmaceutical BMRN	349 M	$ 58.53	-2.03 %	$ 11.2 B	USA
Checkpoint Therapeutics CKPT	-56.2 M	-	-	$ 169 M	USA
Caladrius Biosciences CLBS	-20 M	-	-16.75 %	$ 25.8 M	USA
Alpine Immune Sciences ALPN	-57.8 M	-	-	$ 2.17 B	USA
Clovis Oncology CLVS	-265 M	-	-7.23 %	$ 13 M	USA
Acorda Therapeutics ACOR	-253 M	-	-24.86 %	$ 820 K	USA
Checkmate Pharmaceuticals CMPI	-61.4 M	-	-	$ 231 M	USA
Acasti Pharma ACST	-9.57 M	-	4.01 %	$ 150 M	Canada
CTI BioPharma Corp. CTIC	-93 M	-	-	$ 1.2 B	USA
CohBar CWBR	-12.2 M	-	-15.44 %	$ 2.2 M	USA
Cyclacel Pharmaceuticals CYCC	-11.2 M	-	-5.98 %	$ 34.1 M	USA
Cyclacel Pharmaceuticals CYCCP	-11.2 M	-	-4.36 %	$ 27 M	USA
Cabaletta Bio CABA	-67.7 M	$ 3.25	-1.52 %	$ 3.8 M	USA
Deciphera Pharmaceuticals DCPH	-195 M	-	-	$ 2.18 B	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Capricor Therapeutics CAPR	-22.3 M	$ 25.84	-3.8 %	$ 692 M	USA
Aeterna Zentaris AEZS	-8.37 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-14.8 M	-	-10.17 %	$ 12.2 K	USA
Codexis CDXS	-65.3 M	$ 0.98	-3.92 %	$ 71.9 M	USA
Certara CERT	-1.6 M	$ 7.24	2.7 %	$ 1.16 B	USA
Aeglea BioTherapeutics AGLE	-155 M	-	-	$ 1.01 B	USA
Entasis Therapeutics Holdings ETTX	-47.1 M	-	-	$ 105 M	USA
Evofem Biosciences EVFM	53 M	-	7.55 %	$ 38.1 M	USA
Applied Genetic Technologies Corporation AGTC	-18.4 M	-	-	$ 26.5 M	USA
Coherus BioSciences CHRS	-238 M	$ 1.65	-	$ 155 M	USA
Evelo Biosciences EVLO	-115 M	-	-14.46 %	$ 27.9 M	USA